The MEK1/2 inhibitor selumetinib (AZD6244) has been shown to reduce ERK phosphorylation levels in HCC patients in phase II trials, but has low antitumor activity and poor efficacy in monotherapy.94 The gene discussed is MAP2K1; the disease is hepatocellular carcinoma.